<DOC>
	<DOCNO>NCT01319448</DOCNO>
	<brief_summary>Malaria prophylaxis recommend sickle cell disease patient . In Nigeria , daily proguanil weekly pyrimethamine commonly prescribe regimen , current policy effective due poor compliance drug resistance . Intermittent treatment long act drug regimen administer supervision clinic visit may effective . The aim trial compare tolerability acceptability supervise bimonthly treatment either sulfadoxine-pyrimethamine plus amodiaquine ( SP+AQ ) mefloquine plus artesunate ( MQ+AS ) , daily proguanil . Two hundred seventy patient sickle cell disease attend paediatric sickle cell disease clinic Ilorin hospital meet eligibility criterion parental consent , randomize one three prophylactic regimen : daily proguanil , bimonthly sulfadoxine-pyrimethamine plus amodiaquine , bimonthly mefloquine plus artesunate . Patients ask return clinic every two month whenever sick . At enrollment , study paediatrician conduct physical examination child , collect venous blood sample complete blood cell count biochemical screen , determination G6PD genotype , preparation blood smear malaria microscopy blood spot determination molecular marker resistance . Four day clinic visit , patient interview ( phone , subset , home clinic ) ask compliance adverse event . Participants follow one year . The parent carer encourage bring child Outpatient Department clinic child become unwell . The primary outcome trial tolerability , secondary outcome adherence regimen , incidence malaria number hospitalization 12 month . If bimonthly regimen well tolerate preliminary data study promising , large multicentre trial require determine efficacy .</brief_summary>
	<brief_title>Intermittent Preventive Treatment Malaria Patient With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<criteria>Age 6months old &gt; =5kg Sickle cell clinic attendant Both males female Agree abide study protocol Give inform consent assent Not acutely sick time recruitment Not additional chronic disease Hb genotype SS SC confirm electrophoresis know allergy antimalarial drug use trial , severe illness require urgent admission , treatment sulfadoxinepyrimethamine mefloquine previous 2wks patient cotrimoxazole prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Sickle cell disease</keyword>
	<keyword>Malaria</keyword>
	<keyword>Intermittent Preventive Treatment ( IPT )</keyword>
	<keyword>prophylaxis</keyword>
</DOC>